ERBB2 and breast cancer: We investigated if there were any differences in Ob-R levels with respect to breast cancer subtype and recorded Ob-R cell positivity (+2, +3) rates in patients with HER2+, TNBC, and luminal breast cancer of 62.9%, 58.1%, and 35.3%, respectively (Figure 4A).